EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis

Ioana Agache; Cezmi Akdis; Mubeccel Akdis; Knut Brockow; Tomas Chivato; Stefano Giacco; Thomas Eiwegger; Kilian Eyerich; Ana Giménez‐arnau; Jan Gutermuth; Emma Guttman‐yassky; Marcus Maurer; Graham Ogg; Peck Y. Ong; Liam O’mahony; Jürgen Schwarze; Amena Warner; Thomas Werfel; Oscar Palomares; Marek Jutel; Riccardo Asero; Marta Ferrer Puga; Ignasifigueras Nart; Massimo Gadina; Kenji Kabashima; Kazunari Sugita

doi:10.1111/all.14690

EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis

Ioana Agache, Cezmi Akdis, Mubeccel Akdis, Knut Brockow, Tomas Chivato, Stefano Giacco, Thomas Eiwegger, Kilian Eyerich, Ana Giménez‐arnau, Jan Gutermuth, Emma Guttman‐yassky, Marcus Maurer, Graham Ogg, Peck Y. Ong, Liam O’mahony, Jürgen Schwarze, Amena Warner, Thomas Werfel, Oscar Palomares, Marek JutelRiccardo Asero, Marta Ferrer Puga, Ignasifigueras Nart, Massimo Gadina, Kenji Kabashima, Kazunari Sugita

Research output: Contribution to journal › Article › peer-review

Abstract

Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home‐based), its cost‐effectiveness and long‐term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.

Original language	English
Pages (from-to)	988-1009
Journal	Allergy
Volume	76
Issue number	4
Early online date	7 Dec 2020
DOIs	https://doi.org/10.1111/all.14690
Publication status	Published - Apr 2021

Keywords / Materials (for Non-textual outputs)

atopic dermatitis
dupilumab
GRADE
guideline

Access to Document

10.1111/all.14690Licence: Other

EAACI_Biologicals_Guidelines dupilumab for AD - final versionAccepted author manuscript, 106 KB

https://onlinelibrary.wiley.com/doi/10.1111/all.14690

Cite this

Agache, I., Akdis, C., Akdis, M., Brockow, K., Chivato, T., Giacco, S., Eiwegger, T., Eyerich, K., Giménez‐arnau, A., Gutermuth, J., Guttman‐yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O., ... Sugita, K. (2021). EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis. Allergy, 76(4), 988-1009. https://doi.org/10.1111/all.14690

@article{f196f19b04e8459d91ea2e550b08962f,

title = "EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis",

abstract = "Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home‐based), its cost‐effectiveness and long‐term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.",

keywords = "atopic dermatitis, dupilumab, GRADE, guideline",

author = "Ioana Agache and Cezmi Akdis and Mubeccel Akdis and Knut Brockow and Tomas Chivato and Stefano Giacco and Thomas Eiwegger and Kilian Eyerich and Ana Gim{\'e}nez‐arnau and Jan Gutermuth and Emma Guttman‐yassky and Marcus Maurer and Graham Ogg and Ong, {Peck Y.} and Liam O{\textquoteright}mahony and J{\"u}rgen Schwarze and Amena Warner and Thomas Werfel and Oscar Palomares and Marek Jutel and Riccardo Asero and Puga, {Marta Ferrer} and Ignasifigueras Nart and Massimo Gadina and Kenji Kabashima and Kazunari Sugita",

year = "2021",

month = apr,

doi = "10.1111/all.14690",

language = "English",

volume = "76",

pages = "988--1009",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell",

number = "4",

}

Agache, I, Akdis, C, Akdis, M, Brockow, K, Chivato, T, Giacco, S, Eiwegger, T, Eyerich, K, Giménez‐arnau, A, Gutermuth, J, Guttman‐yassky, E, Maurer, M, Ogg, G, Ong, PY, O’mahony, L, Schwarze, J, Warner, A, Werfel, T, Palomares, O, Jutel, M, Asero, R, Puga, MF, Nart, I, Gadina, M, Kabashima, K & Sugita, K 2021, 'EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis', Allergy, vol. 76, no. 4, pp. 988-1009. https://doi.org/10.1111/all.14690

TY - JOUR

T1 - EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis

AU - Agache, Ioana

AU - Akdis, Cezmi

AU - Akdis, Mubeccel

AU - Brockow, Knut

AU - Chivato, Tomas

AU - Giacco, Stefano

AU - Eiwegger, Thomas

AU - Eyerich, Kilian

AU - Giménez‐arnau, Ana

AU - Gutermuth, Jan

AU - Guttman‐yassky, Emma

AU - Maurer, Marcus

AU - Ogg, Graham

AU - Ong, Peck Y.

AU - O’mahony, Liam

AU - Schwarze, Jürgen

AU - Warner, Amena

AU - Werfel, Thomas

AU - Palomares, Oscar

AU - Jutel, Marek

AU - Asero, Riccardo

AU - Puga, Marta Ferrer

AU - Nart, Ignasifigueras

AU - Gadina, Massimo

AU - Kabashima, Kenji

AU - Sugita, Kazunari

PY - 2021/4

Y1 - 2021/4

N2 - Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home‐based), its cost‐effectiveness and long‐term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.

AB - Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home‐based), its cost‐effectiveness and long‐term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.

KW - atopic dermatitis

KW - dupilumab

KW - GRADE

KW - guideline

U2 - 10.1111/all.14690

DO - 10.1111/all.14690

M3 - Article

SN - 0105-4538

VL - 76

SP - 988

EP - 1009

JO - Allergy

JF - Allergy

IS - 4

ER -

EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis

Abstract

Keywords / Materials (for Non-textual outputs)

Access to Document

Other files and links

Fingerprint

Cite this